Carolyn F. Deacon is one of the leading experts in diabetes with an expertise in incretin hormones and incretin-based therapies. She has held a position as Associate Professor, Department of Biomedical Sciences, University of Copenhagen, Denmark since 2000.
The research of Carolyn F. Deacon centres on the biology of the entero-pancreatic hormones and the therapeutic application of incretin-based therapies. In particular, studies investigating the metabolism of GLP-1, originating from her laboratory in the mid-1990s, have been instrumental in establishing the principle of using DPP-4 inhibition as a novel anti-hyperglycaemic therapy and as a consequence, she is regarded as one of the key opinion leaders in incretin-based therapies and in particular DPP-4 inhibitors.
Carolyn F. Deacon graduated in Zoology (BSc) in 1977 and obtained her PhD in 1983 both at the University of Sheffield, United Kingdom. In 1999, she obtained the D.M.Sc at the Faculty of Health Sciences, University of Copenhagen, Denmark.
Carolyn F. Deacon has held several research positions: Patrick and Irwin Packington Research Fellow in Zoology, University of Sheffield, United Kingdom; Post-doctoral Research Associate, Max-Planck-Gesellschaft, Göttingen, Germany; Post-doctoral Research Associate, University of Sheffield, United Kingdom; Marie Curie Fellow; University of Copenhagen, Denmark; Assistant Research Professor; University of Copenhagen, Denmark; Temporary Lecturer; University of Copenhagen, Denmark and since 2000, as Associate Professor, University of Copenhagen, Denmark.
Carolyn F. Deacon has served on several Scientific Advisory boards and has published over 210 research papers and invited reviews and books. These publications have been cited over 13 000 times (h-index of 61).